懸賞藥品：新雪片、新雪顆粒領(lǐng)取ID：邯鄲學(xué)步66   [更多]

1. Miller J. Ogidigben, Teh-Ching Chu and David E. Potter. Naphazoline-induced neuroendocrine changes Increases in ANP and cGMP levels 2. Robert J. Dockhorn and Thomas G. Duckett. Comparison of Naphcon-A and Its components 3. Mark B, Abelson MD, Salim I, et al. Tolerance and absence of rebound vasodilation following topical ocular decongestant usage 4. Ogidigben MJ, Chu TC, Potter DE. Naphazoline-induced suppression of aqueous humor pressure and flowinvolvement of central and peripheral alpha(2) I(1) receptors 5. The efficacy of long-term treatment with Tolvaptan to prolong the time until dialysis initiation in patients with chronic kidney disease and heart failure 6. Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion 7. Tolvaptan Efficiently Reduces Intracellular Fluid Working Toward a Potential Treatment Option for Cellular Edema 8. Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites 9. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease 10. Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement 11. Nephrol Dial Transplant. 2018 Oct 12. doi 10.1093ndtgfy297. [Epub ahead of print] 12. Nephrol Dial Transplant. 2018 Oct 11. doi 10.1093ndtgfy298. [Epub ahead of print] 13. Development and validation of RP-HPLC method for simultaneous estimation of Ofloxacin and Ornidazole inpresence of Ornidazole Impurity in combined pharmaceutical dosage form 14. Stability-indicating methods for the determination of Ornidazole in the presence of its degradate according to ICH guidelines 15. A sensitive HPLC method of determination of 2-methyl 5-nitro imidazole & reaction mass of intermediates of ornidazole in ornidazole bulk manufacturing 16. Development and validation of a reversed-phase HPLC method for the analysis of ornidazole in pharmaceutical dosage forms 17. On the hydrolytic behavior of tinidazole, metronidazole,   [更多]

標(biāo)題： 1、Morisset M et al. Allergy to cow milk proteins contaminating lactose, common excipient of dry powder inhalers for asthma. J Allergy Clin Immunol 2006; 117(Suppl. 1): 95 2、Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer. 3、Preparation and characterization of a cocrystalline suspension of [LysB28,ProB29]-human insulin analogue. DeFelippis MR1, Bakaysa DL, Bell MA, Heady MA, Li S, Pye S, Youngman KM, Radziuk J, Frank BH 1、Heterocycles, 2001 , vol. 55, # 2 p. 331 - 352 4、R. G. Strickley, L. Liu, and P. Lapresca. Preclinical parenteral and oral formulations of water insoluble molecules. ISSX Meet- ing, Nashville, TN (USA) Abstract # 291 (1999). (Z) 5、465: A possible genetic signature of DNA repair genes in triple negative breast cancers by a NGS approach 4、Systemic exposure to?atorvastatin?between Asian and Caucasian subjects: a combined analysis of 22 studies. 6、 Evaluation of cardiovascular morbidity associated with adherence to?atorvastatin?therapy. 7、Beta-lactam antibiotics: their role in the management of infections in children 8、China type 2 diabetes treatment status survey of treatment pattern of oral drugs users. J Diabetes. 2015 Mar;7(2):166-73 9、Non‐steroidal anti‐inflammatory drugs and upper gastrointestinal bleeding, a post‐marketing surveillance case‐control study 10、Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. 備注：將符合要求文獻(xiàn)的PDF格式打包上傳   [更多]

標(biāo)題： 1、PMID：29241352 Rhabdomyolysis and elevated liver enzymes after rapid correction of hyponatremia due to pneumonia and concurrent use of aripiprazole: a case report 2、PMID：18306096 Hyponatremia in psychiatric patients: update on evaluation and management 3、PMID：20643634 The assessment and treatment of water imbalance in patients with psychosis 4、Marí M, Morales A, Colell A, García-Ruiz C, Fernández-Checa JC. Mitochondrial glutathione, a key survival anti-oxidant. Antioxid Redox Signal. (2009) 11(11)2685-700 5、Yeni D;Effect of α-lipoic acid on sperm quality, reproductive tract measures in thinner exposed rats. 6、PRELIMINARY BASELINE DATA OF HYPERTENSIVE PATIENTS INCLUDED IN THE CATCH (CANDESARTAN ASSESSMENT IN THE TREATMENT OF CARDIAC HYPERTROPHY) STUDY: P1.195 7、Synthesis and antibacterial activity of 1-cyclopropyl-6,8-difluoro-7-(2-substituted 4,6-dihydro-1H-pyrrolo[3,4-d]thiazol-5-yl)-1,4-dihydro-4-oxoquinoline-3-carb oxylic acid 8、Steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected Chinese patients: Expert Review of Clinical Pharmacology: Vol 10, No 7 9、Bioequivalence study of two oral tablet formulations containing tenofovir disoproxil fumarate in healthy volunteers. - PubMed - NCBI 10、 Huiming Ma.Protective function of alpha-lipoic acid on sperm motility and mitochondrial function during goat sperm-mediated gene transfer[J].Small Ruminant Research 99 (2011) 191-198 11、The safety of medical devices containing DEHP plasticized PVC or other plasticizers on neonates and other groups possibly at risk (2015 update). 12、Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies. 將符合標(biāo)題的文獻(xiàn)PDF格式上傳，按照交稿時間的先后確認(rèn)稿件，先到先得   [更多]

本集團(tuán)擬收購一藥廠或混懸劑、顆粒劑、注射劑文號。 藥廠需要提供土地面積，批文數(shù)量，大致報價。 以江浙最佳，海南，廣東亦可。 希望是藥智數(shù)據(jù)庫里面沒有的項目。有轉(zhuǎn)讓意向且尚未轉(zhuǎn)讓的，可提供藥廠具體負(fù)責(zé)轉(zhuǎn)讓事宜的聯(lián)系人及聯(lián)系方式。 不要中介！   [更多]

需求的內(nèi)容在上傳的附件里   [更多]

申報生產(chǎn)許可證B證文件目錄即可，文件內(nèi)容另行協(xié)商。   [更多]

臨床試驗質(zhì)量管理體系文件，包括質(zhì)量手冊、程序文件、標(biāo)準(zhǔn)操作規(guī)程（SOP）和標(biāo)準(zhǔn)化表格；符合2020版GCP法規(guī)要求。源于申辦方/藥廠，非CRO。如果只有SOP和標(biāo)準(zhǔn)化表格也可以。   [更多]

1.完成15 -20 分鐘在線信息調(diào)研內(nèi)容。 2.參與人員：15名研發(fā)外包機(jī)構(gòu)工作人員和15名政府機(jī)構(gòu)工作人員（政府機(jī)構(gòu)為CFDA，環(huán)保局，農(nóng)業(yè)部，科學(xué)院）。 3.參與人員標(biāo)準(zhǔn)：在以上公司或者機(jī)構(gòu)的實驗室內(nèi)從事工作，至少使用過3種及以上實驗室儀器。 4.任務(wù)流程：點(diǎn)擊交稿填寫“我要參與” ---> 加我QQ ---> 參與問答 ---> 上傳截圖 ---> 審核 ---> 付款 備注： 上傳截圖時，請截全屏，以便與我確認(rèn)時間，謝謝。 本人長期推出各類信息的調(diào)研。有意參與者請加QQ：59593161，需要提供個人基本信息。   [更多]

120元尋人將PDF或者WORD文件中的數(shù)據(jù)信息復(fù)制錄入到表格中。文件有800個。 要求： （1）表格錄入的信息必須和文件中字段一一對應(yīng)，藥名必須一一對應(yīng)（基本上是按順序排列的但不確保有例外，這個時候需要一一核實），確保準(zhǔn)確無誤； （2）已經(jīng)有部分做好的例子，可以仿照去做； （3）想做的威客請聯(lián)系QQ2242908064，只有中標(biāo)者本人才會發(fā)給相應(yīng)的文件； （4）完成時間可以協(xié)商，原則上一周以內(nèi)。 注意事項： （1）有些字段是一個含義合并一起錄入，比如適應(yīng)癥有THERAPEUTIC CLAIM/INGREDIENT FUNCTION/PHARMACOLOGICAL ACTION /DESCRIPTION4種表達(dá)，如果只有一個就輸一個，有多個就輸多個(之間用回車隔開）；再比如SPONSOR（MANUFACTURER）也按照上法處理。為方便威客們，這些在字段中已經(jīng)有注明。 （2）有兩個以上化學(xué)名稱的只輸前兩個。 （3）錄入時STRUCTURAL FORMULA不必輸入留為空白。 （4）有些物質(zhì)信息不全，文件中缺失的字段留成空白即可。（尤其是生物大分子，很多沒有分子式） （5）錄入信息必須準(zhǔn)確無誤，不能多也不能少，比如分子量要注明單位的一定要注明，分子式可先不考慮下標(biāo)錄入，MANUFACTURER、CAS等字段的特殊符號必須保留。   [更多]